引言2022 年全球乳腺癌的新发病例数接近 230 万例，死亡病例约为 67 万例，在女性肿瘤中的发病率和死亡率均排名第一[1]。根据 2022 年国家癌症中心的最新统计，中国乳腺癌新发病例数 35.72 万例，在女性癌症中仅次于肺癌，占比为 ...

The NCCN Guidelines for Patients are based on the gold standard NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) used by health care providers worldwide to determine the best cancer ...

PLYMOUTH MEETING, PA [October 6, 2025] — Today, the National Comprehensive Cancer Network ® (NCCN ®)—a nonprofit responsible for globally utilized guidelines for cancer care—is sharing new NCCN ...

The Viz Oncology Suite with NCCN Guidelines delivers personalized, guideline-directed recommendations at the point of careSAN ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...

The NCCN has updated its guidelines on breast, pancreatic, colon, rectal, non-small cell lung, and other cancers. The National Comprehensive Cancer Network (NCCN) has updated its treatment guidelines ...

Medscape Hematology-Oncology is pleased to present the latest update to the NCCN Clinical Practice Guidelines in Oncology™ Prostate Cancer, released in December 2009. The updated NCCN Guideline, ...

Invivyd, Inc. has announced that its investigational monoclonal antibody, PEMGARDA® (pemivibart), has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for ...

The National Comprehensive Cancer Network (NCCN) started the roll-out of a new digital format designed to streamline access and use of the organization's 88 clinical guidelines. The digital makeover, ...

CRANFORD, N.J., Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), today ...

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer ...